Funding analysts at StockNews.com began protection on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) in a analysis notice issued to buyers on Tuesday. The brokerage set a “maintain” ranking on the biotechnology firm’s inventory.
Individually, Maxim Group upgraded shares of Brainstorm Cell Therapeutics from a “maintain” ranking to a “purchase” ranking and set a $2.00 goal value for the corporate in a analysis report on Thursday, July eleventh.
Examine Out Our Newest Inventory Report on Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Buying and selling Up 3.5 %
Shares of BCLI opened at $0.23 on Tuesday. The inventory has a market cap of $16.14 million, a PE ratio of -0.72 and a beta of 0.35. Brainstorm Cell Therapeutics has a 1 yr low of $0.13 and a 1 yr excessive of $0.79. The inventory has a 50 day easy shifting common of $0.30 and a 200-day easy shifting common of $0.41.
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) final launched its quarterly earnings knowledge on Wednesday, August 14th. The biotechnology firm reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). Throughout the identical interval final yr, the enterprise earned ($0.27) EPS. On common, sell-side analysts forecast that Brainstorm Cell Therapeutics will put up -0.19 EPS for the present fiscal yr.
Hedge Funds Weigh In On Brainstorm Cell Therapeutics
A hedge fund not too long ago purchased a brand new stake in Brainstorm Cell Therapeutics inventory. Kingswood Wealth Advisors LLC acquired a brand new place in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Free Report) through the first quarter, in line with the corporate in its most up-to-date Kind 13F submitting with the Securities and Trade Fee. The institutional investor acquired 81,050 shares of the biotechnology firm’s inventory, valued at roughly $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics as of its most up-to-date SEC submitting. 14.33% of the inventory is owned by institutional buyers.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology firm, engages within the improvement and commercialization of autologous mobile therapies for the remedy of neurodegenerative illnesses. The corporate, by way of its NurOwn proprietary cell remedy platform, leverages cell tradition strategies to induce autologous bone marrow-derived mesenchymal stem cells to secrete excessive ranges of neurotrophic components, modulate neuroinflammatory and neurodegenerative illness processes, promote neuronal survival, and improve neurological operate.
Additional Studying
Obtain Information & Scores for Brainstorm Cell Therapeutics Each day – Enter your e-mail deal with beneath to obtain a concise day by day abstract of the most recent information and analysts’ scores for Brainstorm Cell Therapeutics and associated firms with MarketBeat.com’s FREE day by day e-mail e-newsletter.
